NCT00102050

Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication

A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of NM-702 in Subjects With Intermittent Claudication

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 390 (planned)
• Sponsor: Nissan Chemical Industries · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

NM-702 oral tablets are being developed for the treatment of Intermittent Claudication, a primary early stage indication of peripheral arterial disease (PAD). This trial is designed to assess the safety and efficacy of 4 mg and/or 8 mg NM-702 taken twice a day (BID) for 24 weeks to see if it improves peak walking time (PWT) more than placebo for the treatment of Intermittent Claudication.

Detailed description

NM-702 oral tablets are being developed for the treatment of Intermittent Claudication, a primary early stage indication of peripheral arterial disease (PAD). This trial is designed to assess the safety and efficacy of 4 mg and/or 8 mg NM-702 BID for 24 weeks to see if it improves peak walking time (PWT) more than placebo for the treatment of Intermittent Claudication.

Conditions

• Intermittent Claudication
• Peripheral Vascular Disease

Interventions

Type	Name	Description
DRUG	NM-702 (phosphodiesterase inhibitor)

Timeline

• Start date: 2003-04-01
• Completion: 2006-04-01
• First posted: 2005-01-20
• Last updated: 2006-05-19

Locations

17 sites across 1 country: United States